Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
European Journal of Cancer2011Vol. 48(3), pp. 377–384
Citations Over TimeTop 10% of 2011 papers
Gianfranco Pesce, Dirk Klingbiel, Karin Ribi, Abderahim Zouhair, Roger von Moos, Marc Schlaeppi, Clemens B. Caspar, Natalie Fischer, Sandro Anchisi, Solange Peters, Richard Cathomas, Jürg Bernhard, Nina Kotrubczik, Giannicola DʼAddario, Christiane Pilop, Damien C. Weber, Stephan Bodis, Miklos Pless, Michael Mayer, Roger Stupp
Related Papers
- → Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy(2009)61 cited
- → Recurrent Gefitinib-induced Interstitial Lung Disease(2008)28 cited
- Tumour response to gefitinib is associated with EGF- and gefitinib- but not radiation-modulated EGFR expression.(2010)
- [Recurrence of non-small cell lung cancer after successful treatment with gefitinib--report of three cases].(2004)
- [Iressa (gefitinib)].(2003)